Medicines on the market continue to be tested in the interests of continuing patient safety. A recent trial to compare gastric irritation with Vioxx as compared to an NSAID, showed Vioxx in favorable light. However it also showed that some people, who took Vioxx for over 18 months at a stretch, developed cardiac conditions. Merck reported the results to the FDA and voluntarily took the medicine off the market. The relationship between long-term Vioxx therapy and heart condition is not known as yet. The FDA believes that the risks of Vioxx use are rare. We could still find Vioxx back on the market, perhaps with new label warnings and modified dosage. It is not unlike NASA’s suspension of space flights after an adverse event, with subsequent resumption after understanding and dealing with relevant issues.
The Vioxx lawsuit
A higher court may reverse the August 2005 verdict in Texas. Attorneys may establish that the patient in question had a history of cardiac difficulties and that the dosage prescribed was not followed accurately. Merck believes that it has a scientific defense. Media reports of cascading litigation and its effect on Merck could prove to be exaggerated. There is significant evidence of the benefits of all Cox-2 Inhibitors, and their contribution to managing chronic pain. Large numbers of patients need medicines such as Vioxx to remain mobile and to feel well enough to go about their lives, and can take the treatment without undue risk.